![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-1](http://images.happyhaksul.com/thumb/564/563047-0001.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-2](http://images.happyhaksul.com/thumb/564/563047-0002.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-3](http://images.happyhaksul.com/thumb/564/563047-0003.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-4](http://images.happyhaksul.com/thumb/564/563047-0004.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-5](http://images.happyhaksul.com/thumb/564/563047-0005.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-6](http://images.happyhaksul.com/thumb/564/563047-0006.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-7](http://images.happyhaksul.com/thumb/564/563047-0007.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-8](http://images.happyhaksul.com/thumb/564/563047-0008.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-9](http://images.happyhaksul.com/thumb/564/563047-0009.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-10](http://images.happyhaksul.com/thumb/564/563047-0010.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-11](http://images.happyhaksul.com/thumb/564/563047-0011.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-12](http://images.happyhaksul.com/thumb/564/563047-0012.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-13](http://images.happyhaksul.com/thumb/564/563047-0013.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-14](http://images.happyhaksul.com/thumb/564/563047-0014.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-15](http://images.happyhaksul.com/thumb/564/563047-0015.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-16](http://images.happyhaksul.com/thumb/564/563047-0016.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-17](http://images.happyhaksul.com/thumb/564/563047-0017.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-18](http://images.happyhaksul.com/thumb/564/563047-0018.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-19](http://images.happyhaksul.com/thumb/564/563047-0019.gif)
![[재무회계] 제약산업 재무분석-동아제약, 광동제약, 유한양행(영문)-20](http://images.happyhaksul.com/thumb/564/563047-0020.gif)
분야
pptProfitability
ROE
Net profit margin
Stability
Debt- to-equity
Worth index
EPS
DIVIDEND YIELD
ACTIVITY
Conclusion
INVENTORY TURNOVER
This industry is attractive for us
Introduction
-DONG-A
Dong-A Pharmaceutical is
the leading pharmaceutical
company in Korea.
Dong-A's competitive advantage
arises first and foremost
from its continuous focus
on R&D.
Introduction
KWANG DONG
Kwang Dong first started serving the people 48 years ago with the goal of providing scientific benefits of the Oriental medicine.
Financially healthy and strong
competitive edge through constant and sizable R&D investment and updated IT system.
